• Zai Lab closed a private placement of 11,340,000 American depositary shares on October 27, 2026, raising approximately USD 249.93 million gross.
• The USD 22.04 ADS price represents a 7.13% discount to the preceding five-day average ordinary share closing price.
• Net proceeds totaled approximately USD 241.17 million, primarily earmarked for continued global development of zocilurtatug pelitecan, its DLL3-targeting antibody-drug conjugate.
• Placement investors hold 113,400,000 ordinary shares, representing 9.06% of total issued ordinary shares upon completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12386773), on October 28, 2026, and is solely responsible for the information contained therein.